Oramed Pharm stock analysis
Want to see ORMP full AI Analyst Report?
Oramed Pharm (ORMP) Stock Price & Analysis
ORMP Stock Chart & Stats
- Day’s Range
- $3.70 - $4.05
- 52-Week Range
- $2.25 - $5.47
- Previous Close
- $3.71
- Volume
- N/A
- Average Volume (3M)
- 129.36K
- Market Cap
- $161.33M
- Enterprise Value
- $154.55M
- Total Cash (Recent Filing)
- $29.52M
- Total Debt (Recent Filing)
- $1.53M
- Price to Earnings (P/E)
- 1.1
- Beta
- 0.48
- Next Earnings
- Jul 14, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jan 16, 2026
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong Capitalization
Very low debt relative to equity gives Oramed meaningful financial flexibility and reduces near-term solvency pressure. This capitalization can help fund clinical development and absorb operating losses, although its lasting value depends on converting resources into sustainable business performance.
Oral Peptide Delivery Focus
A platform focused on converting traditionally injectable peptide medicines into oral treatments addresses a meaningful usability barrier in drug delivery. If clinical development succeeds, this approach could support differentiated products and broaden the company’s strategic partnering or commercialization opportunities.
Governance Continuity
Re-election of the incumbent board and auditor approval preserve governance continuity during ongoing clinical-stage development. Stable oversight can support consistent capital allocation, regulatory execution, and long-term program decisions, though the votes do not themselves establish commercial or clinical success.
Bears Say
Minimal Commercial Revenue
The absence of a meaningful recurring revenue base shows that Oramed has not yet established a durable commercial engine. This leaves future funding capacity dependent on existing resources, financing, partnerships, or successful product development rather than internally generated operating revenue.
Persistent Operating Losses
Recurring operating losses indicate that the current business model is not covering its ongoing development and corporate costs. Until revenue or product economics improve, continued losses can consume capital, limit strategic flexibility, and make eventual profitability dependent on uncertain clinical and commercialization outcomes.
Negative Cash Generation
Negative operating and free cash flow means reported earnings are not currently translating into cash that can fund the business. Persistent burn increases reliance on the balance sheet over time and may require additional financing or other capital sources if development spending continues.
Oramed Pharm News
ORMP FAQ
What was Oramed Pharm’s price range in the past 12 months?
What is Oramed Pharm’s market cap?
When is Oramed Pharm’s upcoming earnings report date?
How were Oramed Pharm’s earnings last quarter?
Is Oramed Pharm overvalued?
Does Oramed Pharm pay dividends?
What is Oramed Pharm’s EPS estimate?
How many shares outstanding does Oramed Pharm have?
What happened to Oramed Pharm’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Oramed Pharm?
What is the TipRanks Smart Score and how is it calculated?
Oramed Pharm Stock Smart Score
Company Description
Oramed Pharm
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nadav Kidron
- Employees
- 13
- Website
- www.oramed.com
- Address
- 1185 Avenue of the Americas, New York City, NY, 10036, US
Oramed Pharm (ORMP) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |












